. 2020 Feb 2;11(1):9–22. doi: 10.14740/wjon1225

Table 4. Baseline Characteristics According to VSR.

	VSR		P
	High	Low	P
N	20	54
Backgrounds
Sex (N)
Male/female	15/5	33/21	0.41^a
Age (years)
Median (IQR)	74 (69.8 - 77.0)	68 (61.3 - 71.8)	< 0.01^b
< 70/≥ 70 years (N)	5/15	32/22	0.02^a
Smoking status
NS/Ex, CS	3/17	12/42	0.75^a
Histology
Non-SQ/SQ	12/8	43/11	0.13^a
EGFR mutation
(+)/(-) or NA	3/17	8/46	1.00^a
PD-L1 status
≥ 50%/1-49%/< 1%/NA	1/5/2/12	12/10/6/26	0.38^a
ECOG-PS
0 - 1/2/3	11/6/3	42/10/2	0.08^a
Metastatic sites
< 3/≥ 3	11/9	24/30	0.45^a
BMI
Median (IQR)	22.5 (20.4 - 24.0)	22.6 (20.1 - 25.2)	0.84^a
VSR
Median (IQR)
Male	1.87 (1.48 - 3.00)	0.80 (0.52 - 1.07)	< 0.01^b
Female	1.07 (1.01 - 1.15)	0.35 (0.19 - 0.56)	< 0.01^b
Treatment
ICI regimen (N)
Nivo/Pem/Atezo	17/1/2	40/11/3	0.20^a
Previous treatment (N)
Anti-angiogenic drug	9	25	1.00^a
Radiotherapy	7	12	0.37^a
Further line treatment (N)	9	28	0.79^a
ICI efficacy
CR/PR/SD/PD/NE	0/1/3/13/3	3/7/12/30/2
ORR (%) (95% CI)	5.0 (0.1 - 24.9)	18.5 (9.3 - 31.4)	0.27^a
DCR (%) (95% CI)	20.0 (5.7 - 43.7)	40.7 (27.6 - 55.0)	0.11^a
Laboratory data
NLR
Median (IQR)	4.37 (2.39 - 5.93)	3.00 (2.01 - 3.97)	0.13^b
≤ 5/> 5 (N)	12/8	45/9	0.06^a
Albumin (g/dL)
Median (IQR)	3.5 (3.2 - 3.8)	3.6 (3.2 - 4.0)	0.25^b
≥ 3.5/< 3.5 g/dL (N)	11/9	34/20	0.60^a

^aFisher’s exact test. ^bMann-Whitney U test. Atezo: atezolizumab; BMI: body mass index; CI: confidence interval; CR: complete response; CS: current smoker; DCR: disease control rate; ECOG-PS: Eastern Cooperative Oncology Group performance status; EGFR: epidermal growth factor receptor; Ex: ex-smoker; ICI: immune-checkpoint inhibitors; IQR: interquartile range; NE: not evaluated; Nivo: nivolumab; NLR: neutrophil-to-lymphocyte ratio; NS: non-smoker; ORR: overall response rate; PD: progressive disease; PD-L1: programmed cell death ligand 1; Pem: pembrolizumab; PR: partial response; SD: stable disease; SQ: squamous cell carcinoma; TPS: tumor proportion score; VSR: visceral to subcutaneous adipose tissue area ratio.